Skip to content
Open access

Impact of Multi-Cancer Early Detection Test on Late-Stage Cancer Diagnosis

Sep 2026 · New England Journal of Medicine · Vol 395, pp. 1374 - 1386 · 4 citations · ⚡ 1 influential · 30 references
Medicine

TL;DR

In NHS-Galleri, the authors did not observe a reduction in stage III/IV cancers across 12 prespecified cancers after 3 screening rounds when MCED testing was added to standard-of-care.

Abstract

Background NHS-Galleri, a randomized controlled trial, evaluates the clinical utility of a blood-based multi-cancer early detection (MCED) test added to usual care among individuals aged 50-77 years in England. Methods Peripheral blood was collected at up to 3 annual visits. Following baseline blood collection, participants were randomized 1:1 to intervention (blood tested) or control (blood stored) arms. Participants and study personnel were initially blinded. Reductions of stage III/IV (primary endpoint) and IV (key secondary) cancers of 12 prespecified types in intervention vs control were measured ~3 years after the last participant’s randomization. Results Overall, 71,122 and 71,128 participants were randomized to intervention and control arm, respectively. The primary endpoint was not met (incidence rate ratio [IRR; intervention vs control]:1.03 [0.92-1.14], p=0.63). For secondary endpoints, the IRR for stage IV cancer after 3 screening rounds was 0.86 (0.74-1.00). <1% of participants experienced related adverse events, none were serious. Conclusions In NHS-Galleri, we did not observe a reduction in stage III/IV cancers across 12 prespecified cancers after 3 screening rounds when MCED testing was added to standard-of-care. Further follow-up is planned to assess how findings for stage III/IV cancers and the difference in stage IV cancers evolve over time. (Funded by GRAIL, Inc.; ClinicalTrials.gov #NCT05611632)

Read PDF

Similar papers

Open access Sep 2026

Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial

The NHS-Galleri trial was a randomized controlled trial evaluating a multi-cancer early detection (MCED) test added to usual care. We reported elsewhere that the primary endpoint of a reduction in the incidence of stage III/IV cancer diagnoses in the intervention arm versus control arm was not met. Here we report presp...

Richard D. Neal, S. Dolly, Peter Johnson et al. · 5 citations · ⚡1
Open access Sep 2026

Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study

Early cancer detection improves survival; however, most cancer types do not have guideline-recommended screening. We previously reported the first PATHFINDER study that established feasibility of cancer screening with a blood-based multi-cancer early detection (MCED) test that predicts cancer signal origin (CSO) to gui...

N. Nabavizadeh, C. McDonnell, D. Kurbegov et al. · 6 citations · ⚡1
Review Open access Oct 2026

Receipt of surveillance in a population-based sample of survivors of early-onset colorectal cancer.

638 Background: Early-onset colorectal cancer (EOCRC) incidence is rising but data on survival and recurrence compared with late-onset CRC remain limited, contributing to under- and over-use of surveillance. We evaluated receipt of surveillance in a diverse population-based sample of EOCRC survivors and identif...

Christine M. Veenstra, E. Stoffel, S. Hawley et al. · 0 citations
Review Open access Oct 2026

Should current lung cancer screening inclusion criteria be reviewed? Evidence from LUCIA cohort

Abstract Introduction Lung cancer (LC) is the leading cause of cancer-related mortality, largely due to late-stage diagnosis. Thus, early detection improves outcomes and survival. Low-dose computed tomography (LDCT) enables early detection in high-risk populations, although many LC cases fall outside current screening...

J. Orcajo, J. Idoyaga-Uribarrena, A. Vélez-Del-Burgo et al. · 0 citations
Open access Oct 2026

Non-cancer causes of death following cervical cancer diagnosis: a SEER database study.

Non-cancer mortality remains elevated among cervical cancer survivors, including beyond the 5-year landmark, and treatment-group contrasts are strongly affected by disease stage, treatment-selection mechanisms, and unmeasured clinical factors; they should be interpreted as hypothesis-generating rather than causal.

Shan-Shan Wang, Jing-Xin Ding, Xiao-Qin Chen et al. · 0 citations
Sep 2026

Detection Patterns of Breast Cancer Recurrence and Contralateral New Primaries in a Large Integrated Health System.

BACKGROUND Optimizing surveillance for the growing population of breast cancer survivors remains a challenge. Although screening guidelines for initial breast cancer are well established, current surveillance guidelines recommending routine provider examinations rely heavily on expert consensus rather than real-world d...

A. Duffens, Cecile A. Laurent, I. Ergas et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.